MWN109 3 is named as a drug or biological intervention in 3 clinical trials in our China trial register, 1 of which is recruiting. The lead sponsor is Shanghai Minwei Biotechnology Co., Ltd. Registered phases: Phase 2 and Phase 3. Conditions studied include Overweight , Obesity; Type 2 Diabetes Mellitus (T2DM).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07801820 | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus (ClinicalTrials.gov ↗) Type 2 Diabetes Mellitus (T2DM) |
Phase 2 | Recruiting |
| NCT07778693 | Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity (ClinicalTrials.gov ↗) Overweight , Obesity |
Phase 3 | Not yet open |
| NCT07791537 | Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight (ClinicalTrials.gov ↗) Overweight , Obesity |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Overweight , Obesity | 2 |
| Type 2 Diabetes Mellitus (T2DM) | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Minwei Biotechnology Co., Ltd | 3 |
| Register | MWN109 3 trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MWN109 3 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MWN109 3 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.